Dave Clennell joins DxS
This article was originally published in Clinica
Molecular diagnostics company DxS has appointed Dave Clennell director of quality. Mr Clennell has worked in the healthcare industry for 30 years, and was previously director of quality for Lombard Medical Technologies. He has also been employed by Johnson & Johnson, Genzyme and SmithKline Beecham Pharmaceuticals. Manchester, UK-based DxS plans to submit its TheraScreen K-RAS mutation kit to the US FDA "imminently" – it CE marked the test for sale in Europe in January 2008. The diagnostic detects mutations in the KRAS gene that are linked with decreased efficacy of EGFR inhibitors like Amgen's Vectibix (panitumumab), which are used to treat colorectal cancer.